Physician profile
Priya Behari
NPI 1215967211
$1,264.94
in general payments reported to CMS, 2019-2025
20 companies · $53.93 in 2025
The $53.93 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $338 · 2021: $170 · 2022: $171 · 2023: $176 · 2024: $101 · 2025: $53.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.18 | 2019-2024 | |
| Viiv Healthcare Company | $162.66 | 2019-2024 | Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $144.71 | 2019-2025 | Dificid, Prevymis, Zerbaxa |
| Gilead Sciences, INC. | $136.69 | 2019-2021 | |
| Janssen Biotech, INC. | $114.02 | 2019-2021 | |
| Astellas Pharma US INC | $91.73 | 2022-2023 | Cresemba |
| Allergan, INC. | $62.12 | 2019-2020 | |
| Shionogi INC | $61.21 | 2023-2024 | Fetroja |
| Theratechnologies INC. | $60.47 | 2019-2023 | Egrifta, Trogarzo |
| Insmed, INC. | $60.25 | 2020-2023 | Arikayce |
| Melinta Therapeutics, LLC | $34.40 | 2020 | |
| Shire North American Group INC | $28.77 | 2019 | |
| Pfizer INC. | $21.79 | 2020 | |
| Grifols USA, LLC | $20.09 | 2021 | |
| Aimmune Therapeutics, INC. | $19.66 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $18.76 | 2019 | |
| Nabriva Therapeutics, Plc | $16.96 | 2020 | |
| Dynavax Technologies Corporation | $14.13 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.62 | 2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Behari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.